Matrix-metalloproteinases in bronchopulmonary carcinomas.

Histol Histopathol

I.N.S.E.R.M. U. 514, Reims, France.

Published: July 1999

Matrix metalloproteinases (MMPs) represent a group of enzymes involved in the degradation of most of the components of the extracellular matrix and therefore participate in tumoural invasion. MMPs, especially gelatinases A and B, MT1-MMP, the activator of gelatinase A, and stromelysin-3 were found overexpressed in many cancers including bronchopulmonary carcinomas. In vivo observations revealed that fibroblasts are the principal source of production of MMPs. Some of these enzymes such as MT1-MMP and stromelysin 3, displayed a focal stromal localisation near preinvasive and invasive tumour clusters. Furthermore, some tumour cell lines were shown to stimulate the expression of MT1-MMP by fibroblasts. All these in vivo and in vitro results suggest that certain tumour cells produce diffusible factors which could influence the MMP stromal expression. Among these factors, the TCSF (Tumor Collagenase Stimulatory Factor) which is known to upregulate some MMPs in vitro could be a good candidate for this stromal regulation, since it is produced by bronchial tumour cells in vivo. In this review, we address such a cooperation between tumour and stromal cells for the production of MMPs and emphasize their necessity for tumoural progression in bronchopulmonary carcinomas.

Download full-text PDF

Source
http://dx.doi.org/10.14670/HH-14.839DOI Listing

Publication Analysis

Top Keywords

bronchopulmonary carcinomas
12
production mmps
8
tumour cells
8
mmps
5
tumour
5
matrix-metalloproteinases bronchopulmonary
4
carcinomas matrix
4
matrix metalloproteinases
4
metalloproteinases mmps
4
mmps represent
4

Similar Publications

Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).

View Article and Find Full Text PDF

Central nervous system (CNS) metastases of atypical carcinoid tumors are exceptionally rare. Isolated studies suggest a survival benefit in patients who receive whole-brain radiotherapy (WBRT); however, it has been known to have detrimental effects on long-term memory and executive function. Here, we present a case of a patient initially diagnosed with stage IIB bronchopulmonary carcinoid who later developed hepatic and intracranial metastases despite receiving adjuvant systemic therapy over a two-year period.

View Article and Find Full Text PDF

Diagnostic issues in neuroendocrine neoplasms of the lung.

Pathologie (Heidelb)

November 2024

Department of Pathology, TUM School of Medicine and Health, Trogerstr. 18, 81675, Munich, Germany.

Article Synopsis
  • Bronchopulmonary neuroendocrine neoplasms (BP-NENs) make up about 30% of all neuroendocrine neoplasms (NENs) and show similarities to gastroenteropancreatic NENs (GEP-NENs) but differ in classification.
  • BP-NETs (previously known as carcinoids) are classified into typical (TC) and atypical carcinoids (AC), with the new WHO 2022 classification introducing NET G1 and G2 correspondingly.
  • The review emphasizes the significance of the Ki-67 index for accurately classifying BP-NETs, noting that it is not included in their current classification criteria despite its relevance in
View Article and Find Full Text PDF

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids.

Front Endocrinol (Lausanne)

July 2024

Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS, Istituto Auxologico Italiano, Milan, Italy.

Article Synopsis
  • Lung carcinoids (LCs) are rare neuroendocrine tumors in the lungs, representing 20-25% of neuroendocrine tumors and 1-2% of lung cancers, making anti-angiogenic therapies like axitinib (AXI) potential treatment options.
  • In a study, three LC cell lines were treated with AXI to assess its long-term effects, focusing on cell cycle changes, apoptosis, and mechanisms like senescence and mitotic catastrophe.
  • Results indicated that AXI effectively inhibits tumor growth by causing indirect DNA damage, but its efficacy may decrease if DNA damage is repaired, emphasizing the importance of DNA damage in its therapeutic action.
View Article and Find Full Text PDF

A 72-year-old man with productive cough and wheezing was referred to our institution for a growing mass shadow and central bronchiectasis in the right lower lobe on computed tomography. Based on the symptoms, elevated Aspergillus-specific immunoglobulin E levels, and radiological findings, allergic bronchopulmonary mycosis (ABPM) was suspected according to the Japanese clinical diagnostic criteria. The patient refused bronchoscopic examination, and oral prednisolone (0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!